Emerging therapies for inv(16) AML | Zendy

Sridevi Surapally | Zendy; Daniel G. Tenen | Zendy; John Anto Pulikkan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emerging therapies for inv(16) AML

Author(s) -

Sridevi Surapally,

Daniel G. Tenen,

John Anto Pulikkan

Publication year - 2021

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2020009933

Subject(s) - medicine , intensive care medicine , cancer research

The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv(16)(p13q22) acts as a driver oncogene in hematopoietic stem cells and induces AML. This review focuses on novel insights regarding the molecular mechanisms involved in CBFβ-SMMHC–driven leukemogenesis and recent advances in therapeutic approaches to target CBFβ-SMMHC in inv(16) AML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research